10-Q: Passage Bio Narrows Loss, Extends Cash Runway

Passage Bio reported a reduced net loss and extended its cash runway into Q1 2027, driven by cost-cutting measures and strategic out-licensing, despite ongoing clinical trial risks and the impact of a recent reverse stock split.

Summary

• Net loss for the three months ended June 30, 2025, decreased to $9.4 million from $16.0 million in the prior year period.
• Net loss for the six months ended June 30, 2025, decreased to $24.8 million from $32.7 million in the prior year period.
• Cash and cash equivalents increased to $57.6 million as of June 30, 2025, from $37.6 million at December 31, 2024.
• The company expects its existing cash and cash equivalents to fund operating expenses and capital expenditure requirements into the first quarter of 2027.
• Research and development expenses decreased by $4.6 million to $5.8 million for the three months ended June 30, 2025, and by $8.4 million to $13.6 million for the six months ended June 30, 2025, primarily due to workforce reduction and termination of certain research obligations.
• General and administrative expenses decreased by $2.0 million to $4.5 million for the three months ended June 30, 2025, and by $2.4 million to $10.6 million for the six months ended June 30, 2025, due to reduced professional fees and headcount.
• An impairment expense of $2.6 million was recognized for laboratory equipment and other assets in the six months ended June 30, 2025, following the cessation of lab operations in Hopewell, New Jersey.
• The company completed dosing of Cohorts 1 and 2 in the upliFT-D trial for PBFT02 in FTD-GRN patients.
• Biomarker data from the upliFT-D trial showed robust and durable increases in CSF PGRN levels and a favorable change in plasma NfL levels compared to untreated patients.
• The upliFT-D clinical trial protocol was amended to introduce a short course of low dose prophylactic anticoagulation due to serious adverse events (SAEs) experienced by some patients.
• The company effected a 1-for-20 reverse stock split on July 14, 2025, to regain compliance with Nasdaq listing requirements.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company has significantly reduced its net loss, improved its cash position, and shown promising early clinical data for its lead candidate, it remains in early-stage development with a high accumulated deficit and faces substantial future funding needs and inherent risks associated with gene therapy and clinical trials. The strategic out-licensing and cost-cutting are positive steps towards sustainability, but the path to profitability is still long and uncertain.

Positives

• Net loss significantly decreased for both the three-month ($9.4M vs $16.0M) and six-month ($24.8M vs $32.7M) periods ended June 30, 2025, indicating improved financial efficiency.
• Cash and cash equivalents increased to $57.6 million, extending the cash runway into the first quarter of 2027, providing longer operational liquidity.
• Research and development expenses decreased substantially due to strategic restructuring and out-licensing, allowing for more focused resource allocation.
• Positive biomarker data from the upliFT-D trial for PBFT02 showed robust and durable increases in CSF PGRN levels and a favorable impact on plasma NfL, suggesting potential clinical benefit.
• The company received positive regulatory feedback on the clinical pathway for PBFT02 in FTD-C9orf72 and ALS, indicating potential for pipeline expansion.
• Successful out-licensing of lysosomal pediatric programs (GM1, Krabbe, MLD) to Gemma Biotherapeutics provides potential future milestone and royalty payments, reducing direct R&D burden.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $684.0 million as of June 30, 2025.
• Impairment of long-lived assets increased to $2.6 million for the six months ended June 30, 2025, due to the cessation of lab operations and workforce reduction.
• Three out of eight patients in the upliFT-D trial experienced a total of four serious adverse events (SAEs), including venous sinus thrombosis and pulmonary embolism, necessitating protocol amendments.
• Net cash provided by financing activities significantly decreased to $14 thousand for the six months ended June 30, 2025, compared to $8.8 million in the prior year, indicating reduced capital inflow from equity offerings.
• The company's sole clinical stage product candidate, PBFT02, carries high development and regulatory risks, with no guarantee of successful commercialization.
• The 1-for-20 reverse stock split, while aimed at Nasdaq compliance, may adversely affect stock liquidity and investor attraction.

Risks

• The company has a history of operating losses and may not achieve or sustain profitability, anticipating continued losses for the foreseeable future.
• Substantial additional capital will be needed to fund operations and develop product candidates, and financing may not be available on acceptable terms or at all.
• PBFT02 is the sole clinical stage product candidate, and its successful development and commercialization are uncertain.
• Preclinical and clinical development processes are lengthy, expensive, and have uncertain outcomes, potentially leading to delays or inability to complete development.
• Gene therapy is a novel technology, making it difficult to predict development time, cost, and regulatory approval, with only a limited number of gene therapy products approved to date.
• Product candidates may cause undesirable and unforeseen side effects, which could delay or prevent regulatory approval, limit commercial potential, or result in negative consequences.
• Gene therapies are complex and difficult to manufacture, potentially leading to manufacturing problems, delays, or harm to the business.
• Significant competition exists in the rapidly changing biotechnology and pharmaceutical industries, with competitors potentially achieving regulatory approval sooner or developing more effective therapies.
• Reliance on third-party manufacturers (e.g., Catalent) and suppliers for clinical supply and raw materials poses risks of non-compliance, delays, or supply interruptions.
• The pricing, insurance coverage, and reimbursement status of newly approved products are uncertain, potentially limiting marketability and revenue generation.
• Inability to obtain and maintain patent protection or other necessary intellectual property rights could allow competitors to develop similar products.
• Reliance on Gemma Biotherapeutics for preclinical research and development programs carries risks of failure, delay, or termination of collaboration.
• The company's ability to utilize net operating loss carryforwards may be subject to limitations due to ownership changes under Section 382 of the Internal Revenue Code.
• Internal computer systems or those of third parties may suffer security breaches and cyber-attacks, disrupting development programs and potentially compromising data.
• Product liability lawsuits could result in substantial liabilities and limit commercialization of product candidates.
• Changes in patent law or healthcare legislation (e.g., Inflation Reduction Act) could adversely affect the business, pricing, and reimbursement for products.

Future Outlook

The company expects its existing cash and cash equivalents to fund operating expenses and capital expenditure requirements into the first quarter of 2027. Future plans include seeking regulatory feedback on the suspension-based manufacturing process comparability in the second half of 2025, reporting updated interim safety and biomarker data from Dose 2 of PBFT02 in the first half of 2026, and seeking regulatory feedback on registrational trial design in FTD-GRN in the first half of 2026. The company also plans to begin enrolling FTD-C9orf72 patients in Cohort 3 of the upliFT-D study upon site review and acceptance of the amended protocol. Development of the Temporal Lobe Epilepsy (TLE) research program has been paused to reduce operating expenses.

Management Comments

• We are a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases.
• Our primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions.
• We believe we have developed a differentiated approach to developing treatments for central nervous system (CNS) disorders that allows us to select and advance product candidates with a higher probability of technical and regulatory success.
• We expect our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2027.
• We expect our research and development expenses to decrease in the near future as a result of the reduction of our overall workforce by 55% and cessation of our lab operations in Hopewell, New Jersey in January 2025.
• We expect that the reduction of expenses related to the Outlicensed Programs pursuant to the Outlicense Transaction Agreements will offset the increased expenses of advancing our remaining product candidates in the near future.

Industry Context

The gene therapy and neurodegenerative disease fields are characterized by rapid technological change and intense competition. Passage Bio is positioning itself with a focus on one-time gene therapies for critical underlying pathologies, particularly in rare neurodegenerative conditions like FTD-GRN. The industry faces challenges in manufacturing complex biologics, navigating evolving regulatory landscapes for novel therapies, and securing adequate reimbursement for high-cost treatments. The company's strategic out-licensing of pediatric programs to Gemma Biotherapeutics, a newly formed entity with ties to the University of Pennsylvania's Gene Therapy Program, reflects a trend towards specialized collaborations to advance specific pipeline assets and manage operational costs. The ongoing clinical trials for FTD-GRN and planned expansion into FTD-C9orf72 and ALS align with the industry's broader efforts to address diseases with significant unmet medical needs and TDP-43 pathology.

Comparison to Industry Standards

• In the FTD-GRN space, Passage Bio's PBFT02 competes with Prevail Therapeutics Inc. (Eli Lilly & Co), which is also in Phase 1/2 clinical trials for a gene therapy, and AviadoBio Ltd (partnered with Astellas Pharma Inc.), which began enrolling its Phase 1/2 gene therapy trial in 2023. The reported CSF PGRN levels for PBFT02 (mean 12.4-25.9 ng/mL) are notably higher than healthy adult controls (3.3-8.2 ng/mL), suggesting strong biomarker response compared to baseline, which is a positive indicator in early-stage gene therapy development.
• Alector, Inc. (partnered with GSK plc) is conducting a Phase 3 clinical trial with a humanized anti-human sortilin monoclonal antibody for FTD-GRN, representing a different therapeutic modality. Denali Therapeutics Inc. (partnered with Takeda Pharmaceutical Company Limited) is conducting a Phase 1/2 clinical trial for their recombinant progranulin protein, offering a protein replacement approach.
• The average 4% increase in plasma neurofilament light chain (NfL) levels at 12 months post-treatment for PBFT02 (Dose 1) contrasts favorably with an expected 28-29% annual increase in untreated symptomatic FTD-GRN patients, suggesting a potential disease-modifying effect that could differentiate it from natural disease progression and potentially from competitors if sustained.
• For FTD-C9orf72, clinical stage competitors include Transposon Therapeutics, Inc. (small molecule autophagy modulator) and Alector, Inc. (latozinemab). Passage Bio's decision to include FTD-C9orf72 in the upliFT-D trial with PBFT02 positions it against these different therapeutic approaches.
• The occurrence of serious adverse events (SAEs) in 3 out of 8 patients, including venous sinus thrombosis and pulmonary embolism, highlights the inherent safety challenges in gene therapy, which is a common concern across the industry, as seen in other AAV vector trials that have reported liver damage and death. The company's proactive amendment of the protocol to include prophylactic anticoagulation is a response to these safety signals, a practice often adopted in high-risk therapeutic areas.

Management Changes

Corporate Governance

Legal Proceedings

• The company is a defendant in litigation with a former employee who filed a lawsuit in the Court of Common Pleas of Philadelphia County asserting claims for breach of contract and violation of the Pennsylvania Wage Payment and Collection Law.
• The plaintiff contended a binding settlement agreement from February 2020 for 150,000 shares of stock not subject to reverse split; the company argued shares were subject to split (1,692 shares adjusted for 2025 reverse split).
• A trial in October 2024 found an agreement was reached, but shares were subject to the reverse split, awarding damages roughly equal to the company's offer.
• On December 12, 2024, the judge delivered a judgment in the company's favor, finding no binding agreement and no entitlement to damages.
• On December 23, 2024, the plaintiff filed an appeal with the Superior Court of Pennsylvania, which is currently pending. The company intends to continue to defend against this claim.

Related Party Transactions

• The company has a research, collaboration, and license agreement with Gemma Biotherapeutics, Inc. (Gemma), a newly formed genetic medicines company co-founded by Dr. James Wilson, who serves as a Scientific Advisor to Passage Bio.
• Amended Gemma Sublicenses entitle the company to receive an aggregate total of $15.0 million in initial payments for licenses and clinical product supply ($5.0 million previously received, $5.0 million due in May 2025), an additional $5.0 million contingent on business milestones, up to $114.0 million in development and commercial milestone payments, and single-digit royalties.
• Gemma is responsible for all payments due to the Trustees of the University of Pennsylvania (Penn) under the Penn License Agreement related to the Outlicensed Programs (GM1, Krabbe, MLD).
• The company collected $5.0 million in initial payments and $4.7 million in transition services payments from Gemma as of June 30, 2025.
• The company has a restructured research, collaboration, and license agreement with Penn, retaining licenses to programs in FTD, GM1, Krabbe, and MLD, and certain platform technologies.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and continued stock price volatility, despite the recent reverse stock split aimed at Nasdaq compliance.
• Employees experienced a significant workforce reduction of approximately 55% in January 2025, leading to severance costs and potential impacts on morale and retention.
• Patients with neurodegenerative diseases, particularly FTD-GRN, FTD-C9orf72, and ALS, may benefit from the continued development of PBFT02, but also face risks of adverse events and trial delays inherent in gene therapy.
• Creditors and investors are impacted by the company's ongoing net losses and accumulated deficit, though the extended cash runway provides some near-term stability.
• Suppliers and partners, such as Catalent and Gemma, are critical to the company's operations, and their performance or any disputes could affect the company's development timelines and financial condition.

Next Steps

• Seek regulatory feedback on suspension-based manufacturing process comparability in the second half of 2025.
• Report updated interim safety and biomarker data from Dose 2 of PBFT02 in the first half of 2026.
• Seek regulatory feedback on registrational trial design in FTD-GRN in the first half of 2026.
• Begin enrollment in Cohort 3 of the upliFT-D study (5-10 FTD-GRN patients) upon site review and acceptance of the amended protocol.
• Begin enrolling FTD-C9orf72 patients in Cohorts 4 and 5 of the upliFT-D study upon site review and acceptance of the amended protocol.

Key Dates

Recommendation

The company has demonstrated improved financial management by significantly reducing its net loss and extending its cash runway through strategic cost-cutting and out-licensing. The positive early biomarker data for PBFT02 in the upliFT-D trial is encouraging for its lead candidate. However, the company remains in early-stage clinical development, faces substantial risks inherent in gene therapy (including serious adverse events), and will require significant additional capital to reach profitability. The recent reverse stock split and ongoing litigation add layers of uncertainty. Given the balance of promising clinical progress and improved financial efficiency against the high-risk, capital-intensive nature of its business and early development stage, a 'hold' recommendation is appropriate for seasoned investors, suggesting continued monitoring of clinical milestones and financial stability.

Keywords

Gene therapy, Neurodegenerative diseases, FTD-GRN, PBFT02, Clinical trials, Biotechnology, Orphan drug, SEC filing, 10-Q, Financial results, Cash runway, Reverse stock split, Gemma Biotherapeutics, AAV, Lysosomal function